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December 11, 2012:2421–6the 87 with essential RH (35.6%) fulfilled the office systolic BP
criteria (160 mm Hg or 150 mm Hg for diabetics) for RDN;
5 of these patients had out-of-office BP 135/85 mm Hg, and 2
had an eGFR 45 ml/min/1.73 m2. Consequently, only 24
atients were eligible for RDN on both BP and eGFR criteria.
enal artery anatomy was appropriate for RDN on a computed
omography angiogram reviewed by a senior radiologist in only 15
f these 24 patients (62.5%). Therefore, only 1.5% (15 of 1,034) of
ll hypertensive patients or 17.2% (15 of 87) of the patients with
ssential RH referred to our tertiary care hypertension department
ere fully eligible for RDN (see Fig. 1). These proportions might
ven be overestimates, because: 1) spironolactone, which has
roved effective for the treatment of RH (7), was prescribed to only
of 29 patients (24.1%); and 2) compliance with treatment was
ot assessed by systematic plasma or urinary drug determinations.
Our findings demonstrate that percutaneous RDN, whether for
linical trials or specific patients, is limited to a highly selected
raction of patients with RH—even in a specialist hypertension
nit—and that a thorough diagnostic work-up is essential for
ppropriate patient selection. Moreover, the risk associated with this
nvasive procedure also depends on the careful selection of patients
ligible for RDN as well as the experience of the radiologist/
ardiologist conducting the intervention. Finally, further evaluation of
his technique is still required in large, correctly designed clinical trials,
ith ambulatory BP as the primary endpoint.
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Pathophysiologic Mechanisms
Linking Coronary Heart Disease
and Depression
We would like to congratulate Blumenthal et al. (1) for their
interesting paper recently published in the Journal in which
atients with coronary heart disease (CHD) and depression
ymptoms treated with aerobic exercise reached significantly
reater reduction in depression symptoms as compared with the
ontrol group. This reduction in depression symptoms is compa-
able to the sertraline group (1). However, some issues should be
ddressed. First, in the Results section, the authors stated that
ertraline and exercise had a null effect on flow-mediated dilationimprovement in FMD (1.5%; before treatment 2.6%, after
treatment 4.1%) (1). The association between the treated group
and improvement in depression symptoms, the autonomic nervous
system, FMD, and other markers will be assessed by a 2-sided test
(2). This test provides objective information on evaluating the
effects of interventions in clinical trials. This clinical trial confirms
a recent randomized controlled trial that sertraline improved FMD
in those CHD patients treated with 85% statins (3). The data of
this study demonstrated vascular endothelial dysfunction in CHD,
and depression symptoms might be improved beyond the effects of
statins. Nevertheless, the authors did not comment on it in the
Discussion section. Second, Blumenthal et al. (1) found that
physical activity during daily life was associated with significantly
less sympathetic nervous system activity as measured by the
standard deviation of the normal-to-normal R-R intervals as
compared with the sertraline group and the placebo group. This
beneficial effect on the autonomic nervous system does not have a
R2425JACC Vol. 60, No. 23, 2012 Correspondence
December 11, 2012:2421–6notable effect on the endothelial function. This contrasts with
other studies that have demonstrated that physical activity
enhances FMD (4). To measure altered cardiac autonomic tone,
the authors used time-domain components of heart rate vari-
ability. In the Results section, they only gave the standard
deviation of the normal-to-normal R-R intervals. Did they
evaluate other indices of both the parasympathetic and the
sympathetic tone?
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Reply
We thank Dr. Pizzi and colleagues for their interest in our paper
(1) and agree that it is perplexing that although both active
treatments (exercise and sertraline) resulted in improved depres-
sion symptoms, some of our hypothesized mechanisms of risk
associated with depression did not show corresponding improve-
ments. We had hypothesized that the active treatments would
Time-Domain and Frequency-Domain HRV Before and After TreatmentTable 1 Time-Domai and Frequency-Domain HRV B fore nd Af er Trea
Exercise
Before After
Time domain HRV indices
SDANN, ms 104 32 118 38*
Frequency domain HRV indices
Total power, ln ms2 9.3 0.6 9.5 0.7*
ULF power, ln ms2 9.1 0.7 9.3 0.8*
HF power, ln ms2 4.6 1.1 4.8 1.1Values are mean  SD. *A p value 0.05 reflects the contrast between values before and after treatme
HF  high frequency; SDANN  standard deviation of the average R-R intervals over 5-min segments;result in improved flow-mediated dilation (FMD), but as shown in
Table 2 of our paper, a priori contrasts between the 2 active
treatments versus placebo and between exercise versus sertraline
were not statistically significant. Because several research teams,
including our own, have reported previously that impaired FMD is
associated with depression in cardiac patients (2), and that exercise
training resulted in improved FMD (3), we were surprised by these
findings; but as noted in our Discussion, we have no ready
explanation for our failure to confirm these prior observations in
the UPBEAT (Understanding the Prognostic Benefits of Exercise
and Antidepressant Therapy) trial. Our small sample size and the
apparent failure of the randomization procedure to achieve balance
for baseline FMD between treatment groups may have been
contributing factors. Although the sertraline group appears to
show post-treatment improvements in FMD, this observation was
not statistically significant. Nonetheless, we agree that in our
study, the observed direction of change in FMD associated with
sertraline treatment is consistent with the observations reported by
Pizzi et al. (4).
In addition to standard deviation of normal-to-normal R-R
intervals (SDNN), which was our primary biomarker of coronary
heart disease risk and main measure of heart rate variability
(HRV), the letter by Pizzi et al. (4) suggested that we consider
additional time and frequency domain measures of HRV. As seen
in Table 1, we found similar improvements in HRV measured
from the standard deviation of the average R-R intervals over
5-min segments and from total power and ultra-low–frequency
power, but not from high-frequency power. An association be-
tween physical activity and these slower variations in heart rate has
been documented previously (5,6) and is consistent with greater
activity levels and more frequent changes in posture in patients
who underwent exercise training. We note that none of the HRV
measures was significantly changed in the placebo group or the
sertraline-treated group.
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Sertraline Placebo
Before After Before After
104 32 104 33 107 27 107 31
9.2 0.7 9.2 0.6 9.3 0.5 9.4 0.6
9.0 0.8 9.1 0.7 9.1 0.5 9.2 0.6
4.9 1.1 4.7 1.2 4.5 1.2 4.4 1.4tmentnt.
ULF  ultra-low frequency.
